LYMPHOMA & MYELOMA CONNECT is an international group of experts in the field of hematological malignancies and is an initiative of COR2ED. The group discusses the latest scientific and clinical insights, identifies educational needs, and develops educational programmes to support healthcare professionals globally to provide the best possible care to their patients.
Highlights from the ASH Annual Meeting
Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)
Episode 3: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics
Dr. Matthew J. Matasar summarises the highlights in lymphoma from ASH 2021, including POLARIX, CAR-T in LBCL and mosunetuzumab in FL
Authored by LYMPHOMA & MYELOMA CONNECT members, the paper ‘Translating the Biology of Diffuse Large B-cell Lymphoma into Treatment’ provides an overview of recent advances in DLBCL biology and how they can be translated into clinical care.